An ESAT-6-convergent prime-boost vaccination combining recombinant BCG expressing Mycobacterium marinum ESX-1 and ESAT-6/GLA-SE improves TB protection
conferred superior long-term protection against hypervirulent Mtb challenge and significantly reduced pulmonary inflammation. Together, these findings demonstrate that leveraging an ESX-1-competent recombinant BCG platform for targeted ESAT-6 boosting can overcome key limitations of classical BCG vaccination and represents a promising strategy for next-generation TB immunization.
Authors
- Hagyu Kim (ORCID: https://orcid.org/0009-0002-8770-8732)
- Kee Woong Kwon (ORCID: https://orcid.org/0000-0002-6259-855X)
- Hongmin Kim
- Roland Brosch
- Sung Jae Shin
Institutions
- Centre National de la Recherche Scientifique (FR)
- Institut Pasteur (FR)
- Gyeongsang National University (KR)
- Yonsei University (KR)
- Université Paris Cité (FR)
- Yonsei University Health System (KR)
Publication Details
- Journal
- npj Vaccines
- Published
- 2026-04-10
- DOI
- https://doi.org/10.1038/s41541-026-01439-3
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- Ministry of Food and Drug Safety
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea
- National Institutes of Health